DT
KPTI icon

Diversified Trust’s Karyopharm Therapeutics KPTI Stock Holding History

Diversified Trust’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,239
Closed -$28.1K – 915
2024
Q1 		$28.1K Hold
1,239
– – ﹤0.01% 816
2023
Q4 		$16.1K Buy
+1,239
New +$16.7K ﹤0.01% 860

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Diversified Trust's KPTI Position: Q2 2024 in Review

Diversified Trust sold out of Karyopharm Therapeutics (KPTI) in Q2 2024, closing a stake of 1,239 shares — an estimated $28.1K sold.

Diversified Trust first reported a position in KPTI in Q4 2023 and held it in 2 quarters. The position peaked at $28.1K in Q1 2024. 114 funds tracked by Wall St. Rank hold KPTI as of Q2 2024.

  • Diversified Trust reported no remaining Karyopharm Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Diversified Trust sold 1,239 Karyopharm Therapeutics shares in Q2 2024, an estimated $28.1K.
  • Diversified Trust first reported a position in Karyopharm Therapeutics in Q4 2023 and held it in 2 quarters.
  • Diversified Trust's Karyopharm Therapeutics position peaked at $28.1K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2024.

Based on Diversified Trust's 13F filing for Q2 2024, filed 16 Jul 2024.